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Background: Endothelin receptor antagonists (ERA) improve the
prognosis of patients with pulmonary arterial hypertension (PAH).
However, only limited data are available on the effect of treatment
with the ERA bosentan on exercise capacity assessed with cardio-
pulmonary exercise testing (CPX) in patients with PAH or inoperable
chronic thromboembolic pulmonary hypertension (CTEPH). Purpose:
To investigate the effect of the oral, dual-ERA bosentan on exercise
capacity in patients with PAH or inoperable CTEPH by means of CPX.
Methods: Fifteen consecutive PAH (mean age, 47 ± 21 years) and 9
consecutive inoperable CTEPH patients (mean age, 49 ± 12 years)
with World Health Organization Functional Class II to IV were
treated with bosentan. All patients underwent cardiac catheteriza-
tion, echocardiography, and CPX at baseline. CPX was performed
both prior to initiation of bosentan therapy and after 6 months.
Results: In PAH patients, peak VO2 signiﬁcantly increased from
13.8 ± 6.8 mL/kg/min at baseline to 16.8 ± 7.2 mL/kg/min after
6 months (P b 0.01). Similarly, VE/VCO2 slope also signiﬁcantly
decreased from 56.8 ± 22.5 to 48.9 ± 17.5 (P b 0.05). However, in
CTEPH patients, there were no signiﬁcant differences in peak VO2 or
VE/VCO2 slope between the before and after bosentan therapy
values (P = 0.35, P = 0.67, respectively). The medication was well
tolerated by all patients, and there was no evidence of drug-related
liver dysfunction. Conclusions: Bosentan therapy improves exercise
capacity in patients with PAH within a relatively short period.
However, the effect is not seen in patients with CTEPH.
doi:10.1016/j.lfs.2013.12.155
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Background: Bosentan and sildenaﬁl are often administered togeth-
er for the treatment of PAH. Bosentan is a known inducer of CYP3A4 in
chronic use and therefore, the plasma concentration of sildenaﬁl is
decreased almost by half when co-administered. In the course of daily
life, patients tend to take these medicines at the same time in the
morning and the evening. We investigated how the plasma concentra-
tion of sildenaﬁl changed when bosentan/sildenaﬁl was taken before-
hand with the other. Methods: A randomized, open-label crossover
study was conducted in PAH patients of WHO functional class III,
who chronically received both bosentan and sildenaﬁl. Patients were
randomly assigned to either Pattern 1 or 2, both of which consisted of
three phases as follows; phase S: patients take sildenaﬁl 3 h prior to
bosentan, phase B: patients take bosentan 3 h prior to sildenaﬁl, and
phase C: patients take sildenaﬁl and bosentan simultaneously (control).
We collected blood samples on the last day of each phase andmeasured
the plasma concentration of sildenaﬁl using liquid chromatography-
tandem mass spectrometry. Results: Six patients entered the study. In
sildenaﬁl Cmax, phase S was 72.9 ± 40.9 (ng/ml, mean± S.D) and it
was signiﬁcantly lower than phase C (P= 0.0215). Phase B was 99.6 ±
33.9 with no signiﬁcant difference with phase C (P= 0.6173). In
sildenaﬁl AUC0-8, phase S was 108.2 ± 126.4 (h/ng/ml, mean± S.D)
and phase B was 240.7 ± 121.8. Neither phase proved signiﬁcant
difference with that of phase C (203.5 ± 81.3, P = 0.3213 and 0.1999,
respectively). Conclusion: It is indicated that there is a short-term drug
interaction between bosentan and sildenaﬁl which may be relevant to
CYP3A4 metabolism.
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Rationale: A novel dual ETA/ETB receptor antagonist, macitentan,
has been reported to signiﬁcantly reduce morbidity and mortality in
patients with pulmonary arterial hypertension (PAH) (SERAPHIN
study). However, the underlying mechanisms warrant further
preclinical investigations. We have established a rat model of PAH,
which develops severe pulmonary hypertension (PH) with occlusive
pulmonary arteriopathy indistinguishable from that in PAH patients.
This study investigated the effects of macitentan on hemodynamics
and histopathology in the rat model with established severe PAH.
Method and results: Rats received a single subcutaneous injection of
20 mg/kg SU5416, a VEGF blocker, and then exposed to 3-week
hypoxia (10% O2) followed by 5 weeks of normoxia. Eight weeks
after the SU5416 injection, in comparison with normal rats, all rats
developed severe PH (RV systolic pressure: 23 ± 6 vs. 102 ± 15mmHg,
n = 4 or 5 for each, p b 0.001) with RV hypertrophy (the mass ratio of
RV to LV pulse septum: 0.23 ± 0.01 vs. 0.77 ± 0.05, p b 0.001). Five-
week treatmentwithmacitentan (30 mg/kg/day, orally, fromweek 3 to
8) signiﬁcantly reduced RV systolic pressure (41 ± 5 mmHg, n = 6,
P b 0.05) and hypertrophy (0.36 ± 0.03, n = 7, P b 0.005) without
decreasing cardiac output. Also, macitentan signiﬁcantly attenuated
the medial wall thickness and complex occlusive lesions in PAH
rats by histological examination. Conclusion: Chronic treatment with
macitentan markedly hemodynamically and histopathologically im-
proved PAH in SU5416/hypoxia/normoxia-exposed rats. The improve-
ment of arteriopathy may in part contribute to the beneﬁcial effects of
macitentan on PH.
doi:10.1016/j.lfs.2013.12.157
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